A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment.

Trial Profile

A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Resminostat (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SHELTER
  • Sponsors 4SC
  • Most Recent Events

    • 02 Dec 2016 Results of biomarker analysis from SHELTER,SAPHIRE and SHORE trials presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 10 Nov 2016 According to a 4SC media release, full data set of this trial will be presented at an upcoming scientific conference.
    • 06 May 2014 Results published in an 4SC media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top